View this email in your browser
This month in CAR-T research

Welcome to the CAR-T Grease Monkeys newsletter #5. The editoral staff here at the shop has taken a long (but definitely deserved!) break over the holidays to recharge our batteries. Here are the most exciting news from the (clinical) race track, the (academic) garage and in the academic chatter this December (and October and November).

Happy reading and a happy new year, 

News from the race track

1. Real-world data comparing Axi-cel and Tisa-cel:
A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
ASH annual meeting 2019, abstract 1599

2. Double the activation, double the action:
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells
Clin Cancer Res. 2019 Dec 15

3. Patients treated with CD19-specific CARs can still generate an antiviral response:
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.
Blood Adv. 2019 Nov 26

4. ... but can also experience normalization of autoantibody levels:
Chimeric antigen receptor T-cell therapy's role in antiphospholipid syndrome: a case report.
Br J Haematol. 2019 Nov 13

5. A 1:1 ratio of CD4:CD8's lead to milder CRS and highlight's trouble using different scoring systems:
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
Blood. 2019 Dec 12.

6. Anxiety, depression and cognitive difficulties following treatment:
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.
Biol Blood Marrow Transplant. 2020 Jan

7. Arrhythmias, heart failure and death following treatment:
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
J Am Coll Cardiol. 2019 Dec 24

News from the garage

8. C-Jun later, alligator:
c-Jun overexpression in CAR T cells induces exhaustion resistance.
Nature. 2019 Dec

9. Window to the soul captures how fast CARs move in the brain:
Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
Proc Natl Acad Sci U S A. 2019 Nov 26.

10. "We had two bags of grass, 75 pellets of mescaline, five sheets of high-powered blotter acid...and threw them all on our T cells":
Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity.
Blood. 2019 Dec 12.

11. A glycopeptid-specific CAR functional against multiple cancer cell lines:
Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell
JCI Insight. 2019 Nov 1

12. Hacking the break-peddle to increase speed:
Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality.
Nat Commun. 2019 Nov 13

13. Multiplex knockout of TRAV, B2m and PDCD1 enhances efficacy in murine model:
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.
J Immunother Cancer. 2019 Nov 14

14. Where does FMC63 really bind on CD19?
Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design.
Biochemistry. 2019 Dec 3.

15. Natural ligands as extracellular domains in multiple myeloma-specific CAR
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Blood Adv. 2019 Nov

16. Which fuel is better to run your CAR on?
Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity
J Immunother Cancer. 2019 Nov

CAR Talk

17. Craft CAR's versus commercial CAR's:
Letting academic medical centers make CAR-T drugs would save billions
STAT news, 2019 Nov.

18. Consensus guidelines from EBMT:
Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Haematologica. 2019 Nov 21.

19. How to make CARs version 2.0 using synthetic biology:
Paving New Roads for CARs
Trends Cancer. 2019 Oct.

20. What makes the motor run? Review of the intracellular domains:
CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms.
BioDrugs. 2019 Dec

21. Why do anti-BCMA patient relapse?
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
Leukemia. 2020 Jan

CARs elsewhere

22. @ollidufva reviews #ASH19 abstracts and finds a ton of interesting CAR-T stuff (of course)
Our mailing address is:
Departement of clinical
OUH, J.B. Winsløws vej 4
Odense 5000

Add us to your address book

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Departement of clinical · OUH, J.B. Winsløws vej 4 · Odense 5000 · Denmark

Email Marketing Powered by Mailchimp